3.85
+0.17(+4.62%)
Currency In USD
| Previous Close | 3.68 |
| Open | 3.68 |
| Day High | 3.9 |
| Day Low | 3.6 |
| 52-Week High | 6.79 |
| 52-Week Low | 0.6 |
| Volume | 364,607 |
| Average Volume | 1.36M |
| Market Cap | 443.77M |
| PE | -7.55 |
| EPS | -0.51 |
| Moving Average 50 Days | 4.45 |
| Moving Average 200 Days | 2.64 |
| Change | 0.17 |
If you invested $1000 in NovaBridge Biosciences (NBP) since IPO date, it would be worth $308 as of December 04, 2025 at a share price of $3.85. Whereas If you bought $1000 worth of NovaBridge Biosciences (NBP) shares 3 years ago, it would be worth $1,037.74 as of December 04, 2025 at a share price of $3.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
GlobeNewswire Inc.
5 hours ago
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistanceThe Phase 1 ragistomig study achieved its object
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
GlobeNewswire Inc.
Nov 21, 2025 1:00 AM GMT
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
GlobeNewswire Inc.
Oct 29, 2025 10:27 PM GMT
NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines’ strong clinical and commercialization expertise in G